thebench.bio #1 Ecosystem for the Bio-Tech Industry
All Drug Discovery questions

Question 13 of 20 Intermediate Troubleshooting

A candidate is potent in a biochemical assay but weak in cells. How would you triage the discrepancy?

Short answer

Work through the chain between the tube and the target: does the compound get into the cell, stay there, survive metabolism, and compete with the real intracellular conditions. Measure intracellular concentration and target engagement before assuming the biochemical result was wrong.

Why

A biochemical assay presents purified protein, a chosen substrate concentration and no barriers. A cell adds a membrane, efflux pumps, metabolizing enzymes, protein binding in the medium, and physiological substrate levels. Each can cost orders of magnitude.

Competition is a common and quantifiable cause. An ATP-competitive kinase inhibitor tested at 10 micromolar ATP faces several millimolar inside a cell, so apparent potency falls predictably. Permeability failures are common for acids and for large polar molecules.

Efflux transporters remove compound as fast as it enters. Serum albumin in the medium binds lipophilic compounds so that free concentration is a fraction of nominal. Instability in medium or rapid intracellular metabolism lowers exposure over the assay.

Some of the gap is biologically real. The cell may have redundancy, so even full target inhibition gives a small phenotype. That is why target engagement measurement is the dividing line.

If engagement happens at the biochemical potency but the phenotype does not follow, the problem is biology rather than delivery.

How to work it through

  1. Measure the compound's free concentration inside cells and in the medium at the end of the assay.
  2. Run a target engagement assay such as a cellular thermal shift to find the concentration at which binding occurs in cells.
  3. Repeat the biochemical assay at physiological substrate or cofactor concentrations.
  4. Test permeability and efflux, for example with a bidirectional transport assay or by adding an efflux inhibitor.
  5. Check stability in assay medium and in cell lysate over the assay duration.
  6. Compare serum-free and serum-containing conditions to assess protein binding.
  7. Decide from these whether the gap is exposure, competition or biology.

An example

A kinase inhibitor has a biochemical IC50 of 5 nanomolar at 10 micromolar ATP and a cellular EC50 of 3 micromolar. Repeating the biochemical assay at 1 millimolar ATP gives 180 nanomolar. A thermal shift assay shows engagement starting near 300 nanomolar in cells.

Mass spectrometry finds intracellular compound at about one third of nominal. Most of the 600-fold gap is ATP competition, with a smaller contribution from uptake, and the series is steered toward a less ATP-competitive binding mode.

Where the answer stops holding

Measuring free intracellular concentration is technically hard and can be inaccurate for compounds that partition into membranes or lysosomes. Engagement assays do not work for every protein. Closing the gap in one cell line does not guarantee the same in another, since transporter and metabolism profiles differ.

A gap that turns out to be biology does not mean the target is wrong, only that inhibition alone is not sufficient in that model.

A strong answer covers

  • Permeability, efflux, protein binding and metabolism as exposure terms
  • Physiological substrate and cofactor competition
  • Measure intracellular free concentration
  • Target engagement separates delivery from biology
  • Redundancy can make full inhibition give a small phenotype

Common mistakes

  • Comparing a biochemical assay at low ATP with a cellular assay and ignoring competition
  • Assuming nominal medium concentration equals free concentration
  • Dropping a series on the cellular number before checking whether the compound got in